

Edgar Filing: CRITICAL THERAPEUTICS INC - Form 8-K

CRITICAL THERAPEUTICS INC
Form 8-K
July 14, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 14, 2005

Critical Therapeutics, Inc.
(Exact name of registrant as specified in charter)

Delaware (State or other juris- diction of incorporation)	000-50767 (Commission File Number)	04-3523569 (IRS Employer Identification No.)
---	--	--

60 Westview Street, Lexington, Massachusetts (Address of principal executive offices)	02421 (Zip Code)
--	---------------------

Registrant's telephone number, including area code: (781) 402-5700

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On July 14, 2005, Critical Therapeutics, Inc. (the "Company") issued a press release announcing the results of the Company's Phase II study of ZYFLO(R) Filmtab(R) (zileuton tablets) in patients with moderate to severe inflammatory facial acne.

Edgar Filing: CRITICAL THERAPEUTICS INC - Form 8-K

The press release announcing the results of the study is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 14, 2005

CRITICAL THERAPEUTICS, INC.

By: /s/ Paul D. Rubin

Paul D. Rubin, M.D.

President of Finance and Chief Executive
Officer

EXHIBIT INDEX

Exhibit No.

Description

99.1

Press release of Critical Therapeutics, Inc.,
dated July 14, 2005.